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Background: In patients with moderate to severe allergic asthma, clinical effectiveness of
omalizumab, an approved anti-IgE-reacting substance, is usually assessed by pulmonary func-
tion testing (PFT), symptom scores and physicians judgement.
Aims: We postulate that cardiopulmonary exercise testing (CPET) may provide an additional
option to verify symptomatic changes in patients with allergic asthma.
Methods: Ten consecutive patients with allergic asthma were treated with omalizumab. Prior
to and after 16 weeks of treatment all patients underwent PFT and symptom-limited CPET.
Results were compared to 10 asthmatic controls without omalizumab medication. Symptoms
were assessed according to investigators judgement (IGETE).
Results: All 20 patients showed a significantly impaired exercise capacity at baseline [peak
oxygen uptake (VO2) 71  16% predicted]. In patients with omalizumab, peakVO2 increased
from 13.8 (8.4e21.4) to 16.8 (11.2e23.9) ml/kg/min (p < 0.05), VO2 at anaerobic threshold
increased by 22% [9.8 (3.3e15.2) to 12.3 (6.7e14.4) ml/kg/min (p < 0.05)]. There was no
improvement in the controls. The increase in VO2 was significantly correlated to the improve-
ment in symptoms. All patients revealed dynamic hyperinflation under exercise with
a decreasing extent with omalizumab treatment.aeper@gmail.com (C. Scha¨per), glaeser.sven@gmail.com (S. Gla¨ser), felix@uni-greifswald.de
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4 C. Scha¨per et al.Conclusion: This study suggests that CPET may provide additional and useful tools to assess and
verify the individual clinical response to omalizumab treatment. An improvement in exercise
capacity can reliably mirror changes in quality of life and IGETE. Patients with omalizumab
experience significant improvements in their initially impaired exercise capacity. CPET can
be safely accomplished in patients with severe asthma.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Omalizumab, an established and approved anti-immuno-
globulin-E (anti-IgE) reacting substance, has been shown to
be effective in the treatment of patients with moderate to
severe allergic asthma.1e6 Omalizumab related treatment
success has been shown by improved quality of life and
symptom scores, less frequent exacerbations, reduced need
of anti-inflammatory as well as rescue medications and
improved lung function.1e6 Furthermore, a strong evidence
of anti-inflammatory potencies of anti-IgE exists.7,8 To what
extent all these factors may influence exercise capacity in
this patient population has not been studied yet.
Cardiopulmonary exercise testing (CPET) provides the
possibility to reliably quantify exercise capacity in diseased
and healthy subjects by measuring oxygen uptake at
anaerobic threshold (VO2@AT) and peak exercise
(peakVO2).
9 Furthermore, exercise capacity and ventilatory
efficiency e usually expressed as the regression of venti-
lation to carbon dioxide output (VE vs. VCO2 slope) e has
been shown to be well correlated to dyspnoea and survival
in patients with cardiac and pulmonary diseases.10e13 In
patients with impaired lung function due to airflow limita-
tion, exercise induced pulmonary hyperinflation is well
correlated to dyspnoea and exercise capacity.14,15 Both,
exercise capacity and dynamic hyperinflation has been
shown to be potentially improved by bronchodilators.16
The individual effectiveness of omalizumab treatment is
usually assessed by physician’s judgment based on a clinical
evaluation since objective laboratory and technical exam-
inations have not been shown any superiority. The major
aim of this study was to investigate the potential impact of
CPET describing the treatment effects of omalizumab. We
postulate that improvements reported by the patients
under omalizumab may be verified and quantified by gas
exchange analysis within a symptom limited incremental
exercise test.Methods
Study population and treatment protocol
Ten consecutive prospectively assigned adults with severe
allergic asthma due to perennial allergens and positive skin
prick test underwent pulmonary function testing (PFT) and
CPET prior to and after 16 weeks of omalizumab treatment.
Indication for omalizumab therapy was given by insufficient
symptom control under conventional asthma therapy and
patients agreement for additional omalizumab treatment
following the manufacturers recommendations. CPET and
PFT were conducted as integrative parts of their regularvisits in an outpatient clinic for asthma and allergies of the
UniversityHospital. Omalizumab was dosed according
manufacturers’ recommendations (Novartis Pharma
GmbH, Germany) in an open labelled fashion. The results
were compared to 10 consecutive controls with severe
asthma, but without omalizumab treatment. Severe asthma
was defined by a predicted forced expiratory volume in 1 s
(FEV1) <80%, day or night time asthma symptoms more than
twice a week and documented frequent asthma exacerba-
tions, requiring systemic corticosteroids or emergency
services/hospitalization, during the year prior to initiation
of omalizumab.
All 20 patients received at least high dose inhalative
glucocorticosteroids eqivalent to 1000 mg Fluticasone
propionate per day and inhalative long-acting inhaled
b2-agonists at least 4 weeks prior inclusion to the study.
Subjects with known cardiac, muscular or other than
asthmatic pulmonary diseases were excluded from the
study. Investigator ratings of global evaluation of treatment
effectiveness (IGETE) are a tool meanwhile established for
the description of treatment success under omalizumab
therapy.1,17 We categorized IGETE using a scoring system:
2Z significant improvement, 1Z slight improvement,
0Z no change.
All patients gave written informed consent. The study
conformed to the principles of the Declaration of Helsinki
as reflected by an a priori approval of the local Ethics
Committee.
Exercise testing and gas exchange variables
Immediately prior to CPET, each subject underwent a PFT
including spirometry and body plethysmography according
to current recommendations.18 Each subject performed
symptom-limited CPET on a bicycle with ramp wise exercise
increment of 5 Watts per minute. Details of the protocol
and the gas exchange analysis have been published else-
where.19 In the absence of chest pain, ECG abnormalities,
complex arrhythmias or critical blood pressure changes, all
tests were performed symptom-limited (volitional exertion,
dyspnoea or fatigue). Prior to CPET, all patients were
encouraged to reach maximal exhaustion. All tests were
performed according to current guidelines for CPET20,21
with continuous monitoring of gas exchange, 12-lead ECG,
blood pressure and oxygen saturation. Values for oxygen
uptake have been compared to currently published refer-
ence values.22
Statistical analysis
Values are given as median, confidence intervals (CI) and
ranges as outlined. Between-group comparisons were made
Anti-IgE treatment improves oxygen uptake 5using the ManneWhitney U test. A 2-tailed P-value below
0.05 was considered statistically significant.
For the present pilot study it was planed to include 10
patients and 10 controls. Primary objective was, to inves-
tigate whether patients under omalizumab treatment
develop an improvement of oxygen uptake (VO2) as an
objective, verifiable parameter of exercise capacity.
All statistical analyses were performed with SPSS soft-
ware, version 17.0 (SPSS GmbH Software, Munich,
Germany).
Results
All patients treated with omalizumab completed the 16
weeks period without interruptions and complications. All
subjects successfully performed CPET without complica-
tions or premature terminations. Besides omalizumab
initiation in the treatment group and rescue medications all
anti-asthmatic medications remained unchanged. Neither
patients with omalizumab nor controls experienced severe
exacerbation or hospitalisations within the 16 weeks of the
study period. Two of 10 omalizumab treated patients
revealed no symptomatic changes (IGETE 0), 4/10 slight
improvements (IGETE 1), and 4/10 significant improve-
ments (IGETE 2).
PFT and CPET results at baseline and after 16 weeks are
given in Table 1. Both groups showed a significantly
impaired exercise capacity baseline: controls 73% (rangeTable 1 Patient characteristics.
Omalizumab (n Z 10)
Baseline Follow u
Sex [female/male] 7/3
Age [years] 54.5 (29e63)
IgE [I.U./ml] 240 (33e684)
Pulmonary function testing
FEV1 [l] 1.215 (0.35e2.61) 1.55** (0
Rtot [kPa*s/l] 0.625 (0.34e1.4) 0.49 (0.3
FVC [l] 2.26 (1.08e3.83) 2.42 (1.0
ITGV [l] 3.99 (2.446.14) 3.57*þ (
TLC [l] 5.84 (3.67e7.53) 5.44 (3.1
Cardiopulmonary exercise testing
VO2
peak [l/min] 1.1 (0.58e1.86) 1.275* (0
peak [ml/kg/min] 13.8 (8.5e21.6) 16.8* (11
AT [ml/kg/min] 9.83 (3.3e15.2) 12.3* (6.
VE vs. VCO2slope 25.7 (22e34) 25.1 (23
peakVE [l] 33.9 (17.5e59.0) 37.325*
peakVt [l] 1.3 (0.53e1.98) 1.355 (0
peakBF [1/min] 31.5 (26e35) 33 (23e
peak breathing reserve [%] 75 (62e82) 76 (66e
peakVt/IC 0.68 (0.53e0.76) 0.71 (0.5
Patient characteristics at baseline and week 16 (follow up) given as m
p < 0.05 omalizumab vs. controls. n e numbers; FEV1 e forced expir
capacity; ITGV e intrathoracic gas volume measured by body plethysm
anaerobic threshold; VCO2 e carbon dioxide output; VE vs. VCO2 slope
to VCO2; VE e minute ventilation; Vt e tidal volume; BF e brea
FEV1  41)  100 26.57e83) predicted peakVO2; treatment group 63% (44e77)
predicted peakVO2; follow up: 74 (56e82) vs. 70 (56e80) %;
p < 0.05 for in between and follow up comparisons of the
omalizumab group). Median peak expiratory exchange rate
achieved 1.17 (range 0.95e1.35) in the treatment group
(follow up test 1.19; 0.96e1.28 n.s.) and 1.15 (range
0.99e1.25) in controls (follow up 1.17; 1.01e1.24 n.s.).
Omalizumab treated patients revealed a significant
increase in forced expiratory volume in 1 s (FEV1) and
peakVO2. Ventilatory efficiency quantified as VE vs. VCO2
slope was not impaired in both groups. Dynamic flow
volume loops were attainable in 7/10 subjects in the
treatment group and in 7/10 controls. At baseline and after
16 weeks, 6/7 control subjects and 7/7 subjects in the
omalizumab group revealed dynamic hyperinflation with
decreasing inspiratory capacities at peak exercise levels.
Neither omalizumab treated nor control subjects revealed
a peak tidal volume to inspiratory capacity ratio (Vt/IC)
above 0.9 at baseline and follow up. The degree of hyper-
inflation decreased in the treatment group and remained
unchanged in controls. Individual changes in peakVO2 and
VO2@AT are given in Figs. 1 and 2. Changes in peakVO2 in
relation to the clinical response (IGETE) are given in Fig. 3.
Discussion
Patients with severe allergic asthma treated with omali-
zumab reveal a significantly improved exercise capacity.Controls (n Z 10)




.55e2.64) 1.46 (0.93e2.36) 1.58 (0.96e2.38)
e1.03) 0.57 (0.25e0.73) 0.395 (0.2e0.58)
5e3.93) 2.9 (2.72e3.33) 2.935 (2.78e3.2)
2.2e6.06) 3.45 (2.17e5.03) 3.69 (2.42e5.21)
8e7.47) 5.65 (4.59e7.2) 5.895 (4.33e7.56)
.72e2.09) 1.38 (0.87e2.09) 1.34 (1.11e1.45)
.2e23.9) 19.4 (13.8e27.1) 18.8 (13.8e27.8)
7e14.4) 10.5 (6.2e19.5) 11.1 (7.6e14.7)
e33) 26.1 (22e34) 26.5 (20e33)
(21.3e68.4) 47.435 (33.8e68.3) 49.16 (33.7e73.3)
.62e1.9) 1.605 (1.28e1.97) 1.53 (1.19e2.14)
37) 33 (20e36) 32 (24e36)
84) 78 (50e93) 78 (68e91)
1e0.8) 0.67 (0.55e0.81) 0.68 (0.57e0.83)
edian and ranges. * for p < 0.05, ** for p < 0.01 vs. baseline; þ for
atory volume in 1 s; Rtot e airway resistance; FVC e forced vital
ography; TLC e total lung capacity, VO2 e oxygen uptake; AT e
e ventilatory efficiency quantified as slope of the regression of VE
thing frequency. Breathing reserve assessed as 100e(peakVE/
Figure 1 Peak oxygen uptake (VO2) at baseline and follow up
of treated subjects and controls. * for p < 0.05.
Figure 3 Percent changes in peak oxygen uptake (peakVO2)
from baseline to follow up in correlation to clinical response.
No response e IGETE 0; improved e IGETE 1; highly improved e
IGETE 2. * for p < 0.05; ** for p < 0.01; *** for p < 0.001.
6 C. Scha¨per et al.Oxygen uptake at anaerobic threshold and peak exercise
increased remarkably compared to baseline and compared
to controls. The increase in oxygen uptake mirrored the
improvement in symptoms as investigated by IGETE. The
increase in exercise capacity was accompanied by
a decrease in dynamic hyperinflation.
To the best of our knowledge these are the first data
evaluating the potencies of CPET to reliably assess
a medical treatment effect in patients suffering on asthma.
Treatment success due to omalizumab has been described
by improved symptom scores, reduced exacerbations,
improved lung function and a decreased need of anti-
asthmatic medications.1e6 However, all these endpoints
may be biased by investigators and patients. Thus, we
assume that parameters assessed by CPET such as peakVO2
and VO2@AT provide additional reliable options to evaluate
treatment success and to verify changes in symptoms in this
patient population. One may criticize that peak exercise
capacity is dependent on patients’ motivation too.
However, the increase in peakVO2 was accompanied by
a parallel increase in VO2@AT d a motivation independent
parameter.9,23Figure 2 Oxygen uptake at anaerobic threshold (VO2/AT) at
baseline and follow up of treated subjects and controls. * for
p < 0.05.Patients with asthma included in this study show
a significantly impaired exercise capacity in relation to
healthy controls.22 In general, exercise capacity is
depending on multiple confounders influencing pulmonary,
cardiac, circulatory and muscular function or dysfunction.9
Whereas exercise capacity in patients with heart diseases is
usually deteriorated by cardiac dysfunction and ventilator
inefficiency (VE vs. VCO2 slope),
12,13,24 exercise-limiting
factors in pulmonary diseases are heterogeneous.11,15,16,25
The mechanism of dynamic hyperinflation resulting in
decreasing attainable lung volumes under exercise has
been well described in patients suffering on airflow limi-
tation due to chronic obstructive pulmonary diseases
(COPD).14,15 In COPD patients, dynamic hyperinflation
accounts for dyspnoea and exercise intolerance.14,15 To
what extent this mechanism impacts exercise capacity in
patients with allergic asthma has not been described yet.
Except one control all investigated subjects in our study
shared the characteristics of dynamic hyperinflation with
COPD patients. Furthermore, the extent of dynamic
hyperinflation decreased with omalizumab, corresponding
to an improvement in symptoms and exercise capacity.
However, none of the included patients showed ventilatory
constrains feasible to be of exercise limiting quantity since
the Vt/IC ration remained below 0.9. However, this study is
neither powered nor designed to completely clarify exer-
cise-limiting factors in asthma. Thus, it is limited in giving
causal explanations about complex cohesions of exercise
and pulmonary function physiology remains unresolved to
some extent. The mechanisms leading to the improved
exercise capacity under omalizumab treatment and its
associations with traditional methods such as FEV1 has to be
investigated in future studies.
This study may further be criticized for not being blin-
ded and randomized. We understand our results as an initial
attempt to describe a possible new method to evaluate
treatment success due to omalizumab and possibly due to
other anti-asthmatic medications. Furthermore, as in
several studies investigating omalizumab we applied
IGETE1,17 to quantify treatment response in comparison to
CPET. Since IGETE may be influenced by the investigators
judgement we cannot rule out some bias. For future studies
Anti-IgE treatment improves oxygen uptake 7additional questionnaires to assess patients symptoms may
help to reliably measure treatment effects.
Finally, it has to be outlined that in patients with severe
asthma CPET can easily be accomplished and is safe.
Conclusion
This study suggests that CPET may provide additional and
useful tools to assess and verify the individual clinical
response to omalizumab treatment. An improvement in
exercise capacity can reliably mirror changes in quality of
life and IGETE. Patients with omalizumab experience
significant improvements in their initially impaired exercise
capacity. CPET can be safely accomplished in patients with
severe asthma.
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